Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients

Full text
Author(s):
Gouveia, Gisele R. [1] ; Ferreira, Suzete C. [2] ; Siqueira, Sheila A. C. [3] ; de Padua Covas Lage, Luis Alberto [1, 4] ; Hallack Neto, Abrahao E. [5] ; de Oliveira Costa, Renata [6] ; Pereira, Juliana [4, 7]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulos Med Sch FM USP, Lab Med Invest Pathogenesis & Directed Therapy On, Fac Med, Av Dr Eneas Carvalho Aguiar 155, Sao Paulo, SP - Brazil
[2] Prosangue Fdn, Sao Paulo Blood Bank, Dept Mol Biol, Sao Paulo - Brazil
[3] Sao Paulo Univ HC FM USP, Fac Med, Hosp Clin, Dept Pathol, Sao Paulo - Brazil
[4] Sao Paulo Univ FM USP, Fac Med, Dept Hematol Hemotherapy & Cell Therapy, Sao Paulo - Brazil
[5] Univ Juiz De Fora UJF, Dept Hematol & Hemotherapy, Juiz De Fora - Brazil
[6] Ctr Univ Lusiadas FCMS UNILUS, Dept Hematol & Hemotherapy, Santos, SP - Brazil
[7] Nucleus Nonhodgkins Lymphomas & Histiocyt Disorde, Lab Med Invest Pathogenesis & Directed Therapy On, Sao Paulo - Brazil
Total Affiliations: 7
Document type: Journal article
Source: BMC CANCER; v. 20, n. 1 OCT 29 2020.
Web of Science Citations: 0
Abstract

BackgroundOCT-1 gene is a member of the POU-homeodomain family of transcriptional regulators of B-lymphocyte differentiation by controlling expression of B-cell specific genes. BCL-2 gene is a potent inhibitor of apoptosis and it is essential during B-cell differentiation into germinal center. These genes may be expressed in diffuse large B-cell lymphoma (DLBCL), but the role of BCL-2 in its prognosis has been contradictory, and OCT-1 has yet to be tested.MethodsIn this study, we aimed to investigate the prognostic impact of OCT-1 and BCL-2 expression in DLBCL treated in the real world with immunochemotherapy in a single center. BCL-2 and OCT-1 genes were available in 78.5% (77/98) DLBCL patients, and the RNA for quantitative real-time PCR was isolated from formalin-fixed paraffin-embedded samples. The values obtained for gene expression were transformed in categorical variable according to their median.ResultsCohort median age was 54.5years (15-84), 49 (50%) were male, 38/77 (49.4%) and 40/77 (51.9%) presented OCT-1 and BCL-2 expression >= median, respectively. The overall response rate (ORR) in all patients was 68.4% (67/98), 65,3% (64/98) of patients acquired complete response, and 3.1% (3/98) partial response, while 6.1% (6/98) were primary refractory. The median follow-up was 3.77years (95% CI: 3.2-4.1), with 5.43 (95% CI: 2.2-NR) of overall survival (OS) and 5.15years (95% CI: 2.9-NA) of progression free survival (PFS). OCT-1 >= median was associated with shorter OS at univariate analysis (p =0.013; {[}HR] 2.450, 95% CI: 1.21-4.96) and PFS (p =0.019; {[}HR] 2.270, 95%CI: 1.14-4.51) and BCL-2 gene overexpression presented worse PFS (p =0.043, {[}HR] 2.008, 95% CI: 1.02-3.95). At multivariate analysis, OCT-1 overexpression was associated with poor PFS (p =0.035, {[}HR] 2.22, 95% CI: 1.06-4.67).ConclusionIn this study, we showed that overexpression of OCT1 gene was an independent prognostic factor of adverse outcomes in DLBCL. (AU)